Meeting the "Go'' criteria: immunogenicity from HVTN100, a phase 1/2 randomized, double blind, placebo-controlled trial of clade C ALVAC-(R) (vCP2438) and Bivalent Subtype C gp120/MF59 (R) in HIV-uninfected South African adults

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Bekker, L-G; Laher, F; Moodie, Z; Tomaras, G; Grunenberg, N; Allen, M; Daniels, B; Innes, C; Mngadi, K; Malahleha, M; Gilbert, P; Michael, N; Phogat, S; Granados, CD; Kanesa-Thasan, N; Corey, L; Gray, G; McElrath, J

Published Date

  • July 1, 2016

Published In

Volume / Issue

  • 19 /

Published By

Pages

  • 2

Electronic International Standard Serial Number (EISSN)

  • 1758-2652